IDH1 and glioblastoma: Although informing precision treatment decisions against IDH1-mutated (mut) glioblastomas and LGGs has been limited by the lack of clinically relevant translational models, some of them have become refractory to standard therapies after recurrence [3,4,5,21], therefore, a short-term culture system providing appropriate strategies within the time window of the first therapy is urgently needed.